KOLOREKTAL KANSERI TEŞHİS İÇİN YEDİ KAN BİYOBELİRTEÇLERİ ÜZERİNDE KARŞILAŞTIRMALI ANALİZ

Yıl 2020, Cilt: 29 Sayı: 2, 76 - 83, 25.09.2020

Ertugrul Osman Bursalıoğlu

https://doi.org/10.34108/eujhs.560793

Öz

Kanser, insanoğlunun bu yüzyılda karşılaştığı en önemli ölüm nedenlerinden biri haline gelmiştir. Sindirim sistemi, besinlerin insan vücudunda yer aldığı ve işlendiği bir bölge olduğundan, düzensiz ve kötü beslenme, stres, hareketsizlik ve artan çevre kirliliği nedeniyle son yıllarda kolon kanseri artmaktadır. Erken teşhis, kanserde hayatta kalmanın en önemli yollarından biri haline gelmiştir. Son yıllarda, kanser teşhisinde ve tedavisinde yapay zekâ çalışmaları kullanılmaya başlanmıştır. Bu çalışmada, farklı literatürlerden kolon kanseri ile ilgili bazı kan verilerini analiz ederek erken ve pratik tanı için bir çalışma yapılmıştır. Literatürlerden yedi farklı biyobelirteç ve kanla ilgili veri toplama kullanılmış ve WBC, CRP ve CEA adlı biyobelirteçlerin kolon kanseri tespiti ve takibi için kullanılabileceği çıkarımı yapılmıştır.

Anahtar Kelimeler

Colorectal Cancer, Blood, biomarker, Diagnosis, gene

COMPARATIVE ANALYSIS ON SEVEN BLOOD BIOMARKERS TO DIAGNOSE COLORECTAL CANCER

Öz

Cancer has become one of the most important causes of mortality that human beings have faced in this century. Because the digestive system is a region where nutrients are involved and processed in the human body, colorectal cancer (CRC) has been increasing in recent years due to irregular and bad nutrition, stress, immobility and increased environmental pollution. Early detection has become one of the most important ways to stay alive in cancer. In recent years, artificial intelligence studies have begun to be used in the diagnosis and treatment of cancer. In this study, there is a search for early and practical diagnosis by analyzing some blood data acquisition related to colon cancer from different literatures together. Seven different biomarkers and blood-related gene data acquisition were used in the literature and WBC, CRP and CEA type may be used as biomarkers to diagnosis and follow-up for colorectal cancer.

Anahtar Kelimeler

Cancer, Colorectal Cancer, Blood, Diagnosis, Early Detection

Kaynakça

• 1. Hanahan D, Weinberg RA, 2000. The hallmarks of cancer. Cell. 100: 57–70.
• 2. Gupta SC, et al.. 2010. Cancer Metastasis Re. 3: 405-34.
• 3. Ferlay J, Soerjomataram I, and Ervik M. 2013. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide. IARC Cancer Base. 11, Lyon.
• 4. IARC Handbooks of Cancer Prevention Volume 17: Colorectal Cancer Screening. 2018. 256.
• 5. Han J, Kamber M, Pei J. 2012. Data Mining Concepts and Techniques. Third Edition, Elsevier.
• 6. Jothi N. Abdul-Rashid NA, Husain W. 2015. Data Mining in Healthcare, Procedia Computer Science. 72: 306 – 313.
• 7. Peterková A, Michaľčonok G. 2016. Preprocessing Raw Data In Clinical Medicine For A Data Mining Purpose, The Journal of Slovak University of Technolog. 24: 117–122.
• 8. Paik KY, Lee IK, Lee YS, Sung NY, Kwon TS. 2014. Clinical Implications of Systemic Inflammatory Response Markers as Independent Prognostic Factors in Colorectal Cancer Patients, Cancer Research Treatment. 46 : 65-73.
• 9. Kersten C, Louhimo J, Ålgars A, Lahdesmaki A, Cvancerova M, Stenstedt K, Haglund C, Gunnarsson U. 2013. Increased C-reactive protein implies a poorer stage-specific prognosis in colorectal cancer, Acta Oncologica. 52: 1691–1698.
• 10. Aleksandrova K, Jenab M, Boeing H, et al. 2010. Circulating C-Reactive Protein Concentrations and Risks of Colorectal and Rectal Cancer: A Nested Case-Control Study Within the European Prospective Investigation into Cancer and Nutrition, Am J Epidemiol. 172:407–418.
• 11. Toriola AT, Cheng TYD, Neuhouser ML, et al. . 2013. Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers, Int. J. Cancer. 132:2648–2658.
• 12. Wu J, Cai Q, Li H, Cai H, Gao J, Yang G, Zheng W, Xiang YB, and Shu XO. 2013. Circulating C-reactive protein and colorectal cancer risk: a report from the Shanghai Men’s Health Study, Carcinogenesis. 34: 2799–2803.
• 13. Ishızuka M, Nagata H, Takagı K, and Kubota K. 2012. C-Reactive Protein is Associated with Distant Metastasis of T3 Colorectal Cancer, Anticancer Research. 32:1409-1416.
• 14. Saito G, Sadahiro S, Okada K, Tanaka A, Suzuki T, Kamijo A. 2016. Relation between Carcinoembryonic Antigen Levels in Colorectal Cancer Tissue and Serum Carcinoembryonic Antigen Levels at Initial Surgery and Recurrence, Oncology. 91:85–89.
• 15. Su BB, Shi H, Wan J. 2012. Role of serum carcinoembryonic antigen in the detection of colorectal cancer before and after surgical resection, World J Gastroenterol.18: 2121-2126.
• 16. Younesi MR, Aligoudarzi SL, Lashgari M, et al. 2016. Prospective Study of Serum Carcinoembryonic Antigen in Patients with Newly Diagnosed Colorectal Cancer and Healthy Individuals, Annals of Clinical and Laboratory Research. 4:1-5.
• 17. Gao Y, Wang J, Zhou Y, Sheng S, Qian SY, & Huo X. 2018. Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer, Scientific Reports. 8:1-9.
• 18. Amrı R, Bordeıanou LG, Sylla P, Berger D.L. 2013. Preoperative Carcinoembryonic Antigen as an Outcome Predictor in Colorectal Cancer , Journal of Surgical Oncology.
• 19. Sisik A, Kaya M, Bas G, Basak F, Alimoglu O. 2013. CEA and CA 19-9 are Still Valuable Markers for the Prognosis of Colorectal and Gastric Cancer Patients, Asian Pac J Cancer Prev.14: 4289-4294.
• 20. Schell MJ, Yang M, Teer JK. et al. 2016. A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC, Nature Communications. 7: 1-12.
• 21. Liu X, Shan X, Friedl W, Uhlhaas S, Propping PLJ, & Wang Y. 2007. May the APC gene somatic mutations in tumor tissues influence the clinical features of Chinese sporadic colorectal cancers?, Acta Oncologica. 46: 757-762.
• 22. Prutki M, Poljak-Blazi M, Jakopovic M, Tomas D, Stipancic I, Zarkovic N. 2006. Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colorectal cancer, Cancer Letters. 238:188–196.
• 23. Traverso G, Shuber A, Levin B, Johnson C, Olsson L, Schoetz DJ, Hamilton SR, Boynton K, Kınzler KW, Vogelsteın B. 2002. Detectıon Of Apc Mutatıons In Fecal DNA From Patıents With Colorectal Tumors, N Engl J Med. 346: 311-320.
• 24. Fujimori S, Kishida T, Yonezawa M, et al. 2000. Mean Corpuscular Volume May Be A Useful Index Of Risk For Colorectal Adenoma İn Middle-Aged Japanese Men, The American Journal of Gastroenterology. 95:793-797.
• 25. Juha P, Väyrynen JP, Tuomisto A, et al. 2018. Preoperative anemia in colorectal cancer: relationships with tumor characteristics, systemic inflammation, and survival, Scientific Reports. 8:1126.
• 26. Spell DW, Jones DV, Harper WF, Bessman JD. 2004. The value of a complete blood count in predicting cancer of the colorectal, Cancer Detection and Prevention. 28: 37–42.
• 27. Rosty C, Clendenning M, Walsh MD, et al. 2016. Germline mutations in PMS2 and MLH1 in individuals with solitary loss of PMS2 expression in colorectal carcinomas from the Colorectal Cancer Family Registry Cohort, BMJ. 6: e010293.
• 28. Djansugurova L, Zhunussova G, Khussainova E, Iksan O, Afonin G, Kaidarova D, Matejcic M, and Parker MI. 2014. Screening the APC, MLH1, MSH2 and TP53 Mutations in Patients with Early Onset of Colorectal Cancer, J Carcinog Mutagen. 5:1000197.
• 29. Dowty JG, Wi AK, Buchanan D.D., et al. 2013. Cancer risks for MLH1 and MSH2 mutation carriers, Hum Mutat. 34: 22262.
• 30. Brim H, Mokarram P, Naghibalhossaini F. et al. 2008. Impact of BRAF. MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study, Molecular Cancer. 7:68:1-11.